Acadia Pharmaceuticals | ACAD - Net Income


Acadia Pharmaceuticals reported $3.64M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Cara Therapeutics USD -5.53M 621K Sep/2025
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY -3.25B 20.43B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
J&J USD 5.24B 119M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Prothena USD -21.59M 14.95M Dec/2025
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026